Global Tuberculosis (TB) Diagnostics Market to Reach US$ 4.15 Billion by 2031, Driven by Molecular Testing Expansion and Global TB Control Initiatives | QY Research

Market Overview -

The global Tuberculosis (TB) Diagnostics market was valued at US$ 3,070 million in 2024 and is projected to reach US$ 4,149 million by 2031, growing at a CAGR of 4.5% during the forecast period 2025-2031.

According to QY Research, the newly released report titled "Tuberculosis (TB) Diagnostics Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031" presents a comprehensive evaluation of global market dynamics, competitive positioning, technology trends, and regional demand patterns shaping the future of TB diagnostics worldwide.

Get Full PDF Sample Copy of the Report: (Including Full TOC, Tables & Charts):
https://www.qyresearch.in/request-sample/medical-care-tuberculosis-tb-diagnostics-market-share-and-ranking-overall-sales-and-demand-forecast-2025-2031

Disease Background and Diagnostic Importance
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (MTB), most commonly affecting the lungs but also capable of impacting other organs. While many infections remain latent and asymptomatic, approximately 10% of latent TB cases progress to active disease, which can be fatal if left untreated. Symptoms of active TB include persistent cough (often with blood-containing sputum), fever, night sweats, and weight loss.
Early and accurate diagnosis is critical for controlling TB transmission, guiding appropriate treatment, and reducing mortality. As a result, diagnostics play a central role in global TB elimination strategies and public health programs.

Key Market Drivers
The TB diagnostics market is being driven by the persistent global burden of tuberculosis, particularly in high-prevalence regions across Asia-Pacific, Africa, and parts of Latin America. International efforts aligned with the WHO End TB Strategy have significantly increased funding for TB screening, surveillance, and early detection programs.

Technological advancements are transforming the diagnostic landscape. The adoption of rapid molecular diagnostics, AI-assisted chest X-ray screening, and point-of-care testing platforms has improved diagnostic accuracy, reduced turnaround times, and enabled same-day treatment decisions. These tools are especially valuable for screening high-risk populations such as people living with HIV, healthcare workers, migrants, and incarcerated individuals.

Integration of TB diagnostics into broader respiratory disease programs and universal healthcare initiatives has further expanded testing capacity and market reach.

Market Challenges and Barriers
Despite notable progress, the TB diagnostics market continues to face significant challenges. Limited access to advanced diagnostic technologies in low- and middle-income countries remains a major barrier, driven by inadequate laboratory infrastructure and shortages of trained personnel. High costs associated with molecular assays and imaging systems-along with ongoing expenses for consumables and maintenance-restrict widespread adoption.
Logistical and regulatory hurdles, particularly in rural and remote areas, slow down deployment of diagnostic platforms. Additionally, inconsistent diagnostic algorithms and variable reimbursement policies across countries hinder standardized implementation and weaken the overall impact of TB control efforts.

Competitive Landscape
The global TB diagnostics market is moderately concentrated, with leading multinational diagnostics companies holding a strong position through proprietary technologies, global distribution networks, and public-private partnerships. Key players profiled in the report include
► Danaher
► Roche
► Thermo Fisher Scientific
► BD
► Abbott.

The top five manufacturers collectively account for approximately 33% of global market revenue, reflecting strong competition alongside continued opportunities for innovation and regional expansion. Other notable participants include Hologic, Qiagen, bioMérieux, Hain Lifescience, and Oxford Immunotec.

Segmentation Insights
By diagnostic type, rapid molecular diagnostics represent the fastest-growing segment, supported by their high sensitivity, ability to detect drug resistance, and suitability for decentralized testing. Traditional methods such as sputum smear microscopy and culture-based diagnostics remain widely used in resource-limited settings due to lower cost, despite longer turnaround times.

From an application perspective, diagnostic laboratories account for a significant share of testing volume, while hospitals are increasingly adopting advanced molecular and imaging-based solutions as part of integrated TB care pathways.

Regional Outlook
The Asia-Pacific region is the largest market for TB diagnostics, accounting for over 40% of global revenue, driven by high disease prevalence and large-scale national TB programs in countries such as India, China, and Indonesia. The Americas and Europe together represent around 40% of the market, supported by strong healthcare infrastructure, advanced diagnostic adoption, and targeted screening of vulnerable populations.

The Middle East & Africa region continues to present long-term growth opportunities as international funding and infrastructure development gradually improve diagnostic access.

Market Segmentation Highlights

By Type
► Culture-Based Diagnostics
► Sputum Smear Microscopy
► Rapid Molecular Diagnostics
► Others

By Application
► Diagnostic Laboratories
► Hospitals

By Region
► North America
► Europe
► Asia Pacific
► South America
► Middle East & Africa

Why This Report Matters
► Detailed global and regional revenue forecasts through 2031
► Comprehensive company market share and competitive ranking analysis
► Insights into molecular diagnostics, AI-based imaging, and point-of-care testing trends
► Evaluation of policy, funding, and access challenges in TB control
► Strategic guidance for diagnostics companies, public health agencies, and investors

Request for Pre-Order / Enquiry Link:
https://www.qyresearch.in/pre-order-inquiry/medical-care-tuberculosis-tb-diagnostics-market-share-and-ranking-overall-sales-and-demand-forecast-2025-2031

Table of Content:

1 Market Overview
1.1 Tuberculosis (TB) Diagnostics Product Introduction
1.2 Global Tuberculosis (TB) Diagnostics Market Size Forecast (2020-2031)
1.3 Tuberculosis (TB) Diagnostics Market Trends & Drivers
1.3.1 Tuberculosis (TB) Diagnostics Industry Trends
1.3.2 Tuberculosis (TB) Diagnostics Market Drivers & Opportunity
1.3.3 Tuberculosis (TB) Diagnostics Market Challenges
1.3.4 Tuberculosis (TB) Diagnostics Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Tuberculosis (TB) Diagnostics Players Revenue Ranking (2024)
2.2 Global Tuberculosis (TB) Diagnostics Revenue by Company (2020-2025)
2.3 Key Companies Tuberculosis (TB) Diagnostics Manufacturing Base Distribution and Headquarters
2.4 Key Companies Tuberculosis (TB) Diagnostics Product Offered
2.5 Key Companies Time to Begin Mass Production of Tuberculosis (TB) Diagnostics
2.6 Tuberculosis (TB) Diagnostics Market Competitive Analysis
2.6.1 Tuberculosis (TB) Diagnostics Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Tuberculosis (TB) Diagnostics Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tuberculosis (TB) Diagnostics as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Culture-Based Diagnostics
3.1.2 Sputum Smear Microscopy
3.1.3 Rapid Molecular Diagnostics
3.1.4 Others
3.2 Global Tuberculosis (TB) Diagnostics Sales Value by Type
3.2.1 Global Tuberculosis (TB) Diagnostics Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Tuberculosis (TB) Diagnostics Sales Value, by Type (2020-2031)
3.2.3 Global Tuberculosis (TB) Diagnostics Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Diagnostic Laboratories
4.1.2 Hospitals
4.2 Global Tuberculosis (TB) Diagnostics Sales Value by Application
4.2.1 Global Tuberculosis (TB) Diagnostics Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Tuberculosis (TB) Diagnostics Sales Value, by Application (2020-2031)
4.2.3 Global Tuberculosis (TB) Diagnostics Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Tuberculosis (TB) Diagnostics Sales Value by Region
5.1.1 Global Tuberculosis (TB) Diagnostics Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Tuberculosis (TB) Diagnostics Sales Value by Region (2020-2025)
5.1.3 Global Tuberculosis (TB) Diagnostics Sales Value by Region (2026-2031)
5.1.4 Global Tuberculosis (TB) Diagnostics Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
5.2.2 North America Tuberculosis (TB) Diagnostics Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
5.3.2 Europe Tuberculosis (TB) Diagnostics Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
5.4.2 Asia Pacific Tuberculosis (TB) Diagnostics Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
5.5.2 South America Tuberculosis (TB) Diagnostics Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
5.6.2 Middle East & Africa Tuberculosis (TB) Diagnostics Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Tuberculosis (TB) Diagnostics Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
6.3 United States
6.3.1 United States Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
6.3.2 United States Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Tuberculosis (TB) Diagnostics Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
6.4.2 Europe Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Tuberculosis (TB) Diagnostics Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
6.5.2 China Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
6.5.3 China Tuberculosis (TB) Diagnostics Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
6.6.2 Japan Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Tuberculosis (TB) Diagnostics Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
6.7.2 South Korea Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Tuberculosis (TB) Diagnostics Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
6.8.2 Southeast Asia Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Tuberculosis (TB) Diagnostics Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
6.9.2 India Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
6.9.3 India Tuberculosis (TB) Diagnostics Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Danaher
7.1.1 Danaher Profile
7.1.2 Danaher Main Business
7.1.3 Danaher Tuberculosis (TB) Diagnostics Products, Services and Solutions
7.1.4 Danaher Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
7.1.5 Danaher Recent Developments
7.2 Roche
7.2.1 Roche Profile
7.2.2 Roche Main Business
7.2.3 Roche Tuberculosis (TB) Diagnostics Products, Services and Solutions
7.2.4 Roche Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
7.2.5 Roche Recent Developments
7.3 Thermo Fisher Scientific
7.3.1 Thermo Fisher Scientific Profile
7.3.2 Thermo Fisher Scientific Main Business
7.3.3 Thermo Fisher Scientific Tuberculosis (TB) Diagnostics Products, Services and Solutions
7.3.4 Thermo Fisher Scientific Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
7.3.5 Thermo Fisher Scientific Recent Developments
7.4 BD
7.4.1 BD Profile
7.4.2 BD Main Business
7.4.3 BD Tuberculosis (TB) Diagnostics Products, Services and Solutions
7.4.4 BD Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
7.4.5 BD Recent Developments
7.5 Abbott
7.5.1 Abbott Profile
7.5.2 Abbott Main Business
7.5.3 Abbott Tuberculosis (TB) Diagnostics Products, Services and Solutions
7.5.4 Abbott Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
7.5.5 Abbott Recent Developments
7.6 Hologic
7.6.1 Hologic Profile
7.6.2 Hologic Main Business
7.6.3 Hologic Tuberculosis (TB) Diagnostics Products, Services and Solutions
7.6.4 Hologic Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
7.6.5 Hologic Recent Developments
7.7 Qiagen
7.7.1 Qiagen Profile
7.7.2 Qiagen Main Business
7.7.3 Qiagen Tuberculosis (TB) Diagnostics Products, Services and Solutions
7.7.4 Qiagen Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
7.7.5 Qiagen Recent Developments
7.8 BioMerieux
7.8.1 BioMerieux Profile
7.8.2 BioMerieux Main Business
7.8.3 BioMerieux Tuberculosis (TB) Diagnostics Products, Services and Solutions
7.8.4 BioMerieux Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
7.8.5 BioMerieux Recent Developments
7.9 Hain Lifescience
7.9.1 Hain Lifescience Profile
7.9.2 Hain Lifescience Main Business
7.9.3 Hain Lifescience Tuberculosis (TB) Diagnostics Products, Services and Solutions
7.9.4 Hain Lifescience Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
7.9.5 Hain Lifescience Recent Developments
7.10 Oxford Immunotec
7.10.1 Oxford Immunotec Profile
7.10.2 Oxford Immunotec Main Business
7.10.3 Oxford Immunotec Tuberculosis (TB) Diagnostics Products, Services and Solutions
7.10.4 Oxford Immunotec Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
7.10.5 Oxford Immunotec Recent Developments
8 Industry Chain Analysis
8.1 Tuberculosis (TB) Diagnostics Industrial Chain
8.2 Tuberculosis (TB) Diagnostics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Tuberculosis (TB) Diagnostics Sales Model
8.5.2 Sales Channel
8.5.3 Tuberculosis (TB) Diagnostics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

QY Research PVT. LTD.
315 Work Avenue,
Raheja Woods,
6th Floor, Kalyani Nagar,
Yervada, Pune - 411060,
Maharashtra, India
India: (O) +91 866 998 6909
USA: (O) +1 626 295 2442
Email: hitesh@qyresearch.com
Web: www.qyresearch.in

About QY Research
QY Research is a leading global market research and consulting firm providing authoritative insights across diagnostics, medical devices, pharmaceuticals, and public health markets. Through rigorous methodologies and deep domain expertise, QY Research enables clients to make informed, data-driven strategic decisions.

This release was published on openPR.